Purple Biotech ( (PPBT) ) has issued an announcement.
On March 18, 2025, Purple Biotech Ltd. announced the availability of an updated company presentation on its website. The presentation highlights the company’s progress in developing first-in-class oncology therapies, including CM24, a CEACAM1-targeting therapy, which has shown clinical proof of concept and potential in treating pancreatic cancer and other major indications. The announcement underscores Purple Biotech’s strategic positioning to advance its clinical milestones and leverage its innovative drug pipeline to address significant unmet medical needs in oncology.
More about Purple Biotech
Purple Biotech is a biotechnology company focused on developing first-in-class drug candidates for cancer treatment. The company operates in the oncology sector, identifying promising therapies to address cancers with high unmet medical needs. It is involved in advancing clinical-stage drugs and a preclinical immuno-engagers platform, with a global operation and a cash runway extending into mid-2026.
YTD Price Performance: -39.00%
Average Trading Volume: 52,025
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $7.4M
See more data about PPBT stock on TipRanks’ Stock Analysis page.